BRD2 and central nervous system cancer: Gliomas have significantly higher BRD2 and BRD4 levels than control tissues, and the mRNA and expression levels of BRD4 are closely related to the tumor subtypes and the overall survival rate of the patients, indicating that I-BET151 can have a therapeutic effect on gliomas (6, 48).